Jazz Pharmaceuticals plc Operating Lease Liability
Jazz Pharmaceuticals plc (JAZZ) had Operating Lease Liability of $65.17 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-02-24
- 2025-12-31: Operating Lease, Liability $65.17M.
- 2024-12-31: Operating Lease, Liability $53.27M.
- 2023-12-31: Operating Lease, Liability $78.24M.
- 2022-12-31: Operating Lease, Liability $87.39M.
| Period end | Operating Lease, Liability |
|---|---|
| 2025-12-31 | $65.17M 10-K · filed 2026-02-24 |
| 2024-12-31 | $53.27M 10-K · filed 2025-02-26 |
| 2023-12-31 | $78.24M 10-K · filed 2024-02-28 |
| 2022-12-31 | $87.39M 10-K · filed 2023-03-01 |
| 2021-12-31 | $102.56M 10-K · filed 2022-03-01 |
| 2021-09-30 | $106.00M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $177.05M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $150.07M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $154.49M 10-Q · filed 2021-05-04 |
| 2020-09-30 | $155.00M 10-Q · filed 2020-11-02 |
| 2020-06-30 | $157.03M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $159.47M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $163.95M 10-K · filed 2021-02-23 |
| 2019-09-30 | $165.15M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $165.01M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $162.74M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |